Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function
| Autor: | Heribert Staudinger, Marcella Ruddy, Yamo Deniz, Naimish Patel, Jonathan Corren, Paul Rowe, Ariel Teper, David Langton, Neil M.H. Graham, Lawrence Sher, Ian D. Pavord, Megan S. Rice, Salman Siddiqui, Philip G. Bardin, Hae-Sim Park, Alberto Papi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty education.field_of_study Exacerbation business.industry Population Placebo medicine.disease Dupilumab Gastroenterology respiratory tract diseases Internal medicine Post-hoc analysis Exhaled nitric oxide medicine Immunology and Allergy Biomarker (medicine) business education Asthma |
| Zdroj: | Journal of Asthma and Allergy. 13:701-711 |
| ISSN: | 1178-6965 |
| Popis: | Purpose The Phase 3 LIBERTY ASTHMA QUEST study in patients aged ≥12 years with uncontrolled, moderate-to-severe asthma demonstrated the efficacy and safety of dupilumab 200 mg and 300 mg every 2 weeks (q2w) vs matched placebo in the overall population. This post hoc analysis assessed dupilumab efficacy by disease severity as evidenced by baseline % predicted forced expiratory volume in 1 second (FEV1) and dose of inhaled corticosteroids (ICS). Patients and Methods Severe asthma exacerbation rates, change from baseline in FEV1, asthma control, quality of life, and fractional exhaled nitric oxide (FeNO) levels over the 52-week treatment period were assessed in patients with elevated type 2 inflammation biomarkers stratified by ICS dose and FEV1% predicted at baseline. Results In patients with elevated baseline eosinophils, dupilumab 200 mg and 300 mg q2w vs placebo reduced severe exacerbation rates by 50% (P=0.06) and 67% (P=0.001), respectively, in those with medium-dose ICS/FEV1% predicted 60-90%, and by 59% (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|